Adjuvant radiotherapy for stage I endometrial cancer: systematic review and meta-analysis.

The role of adjuvant radiotherapy in stage I endometrial cancer following surgery remains unclear. The management for these patients varies widely, particularly in stage I patients with different risk factors. Using the methodology of Cochrane Collaboration, we did a systematic and meta-analysis of...

Full description

Bibliographic Details
Main Authors: Kong, A, Simera, I, Collingwood, M, Williams, C, Kitchener, H
Format: Journal article
Language:English
Published: 2007
_version_ 1826276591667249152
author Kong, A
Simera, I
Collingwood, M
Williams, C
Kitchener, H
author_facet Kong, A
Simera, I
Collingwood, M
Williams, C
Kitchener, H
author_sort Kong, A
collection OXFORD
description The role of adjuvant radiotherapy in stage I endometrial cancer following surgery remains unclear. The management for these patients varies widely, particularly in stage I patients with different risk factors. Using the methodology of Cochrane Collaboration, we did a systematic and meta-analysis of all know randomised controlled trials which compared adjuvant radiotherapy versus no radiotherapy following surgery for patients with stage I endometrial cancer. The meta-analysis was carried out on four trials (three published and one unpublished) and a total of 1770 patients. The addition of pelvic external beam radiotherapy to surgery reduced locoregional recurrence, a relative risk (RR) of 0.28 [95% confidence interval (CI) 0.17-0.44, P < 0.00001], which is a 72% reduction in the risk of pelvic relapse (95% CI 56% to 83%) and an absolute risk reduction of 6% (95% CI of 4% to 8%). The reduction in the risk of locoregional recurrence did not translate into a reduction in the risks of death from all causes, endometrial cancer death or distant recurrence. A subgroup analysis showed a trend towards the reduction in the risks of death from all causes and endometrial cancer in patients with multiple high risk factors (including stage 1c and grade 3). External beam pelvic radiotherapy should be considered in patients with multiple high-risk features including stage 1c and grade 3. However, it carries an inherent risk of damage and toxicity and should be avoided in stage 1 endometrial cancer patients with no high risk factors.
first_indexed 2024-03-06T23:16:16Z
format Journal article
id oxford-uuid:673d3733-eac4-4daf-be9e-cef4bf63ab5a
institution University of Oxford
language English
last_indexed 2024-03-06T23:16:16Z
publishDate 2007
record_format dspace
spelling oxford-uuid:673d3733-eac4-4daf-be9e-cef4bf63ab5a2022-03-26T18:36:55ZAdjuvant radiotherapy for stage I endometrial cancer: systematic review and meta-analysis.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:673d3733-eac4-4daf-be9e-cef4bf63ab5aEnglishSymplectic Elements at Oxford2007Kong, ASimera, ICollingwood, MWilliams, CKitchener, HThe role of adjuvant radiotherapy in stage I endometrial cancer following surgery remains unclear. The management for these patients varies widely, particularly in stage I patients with different risk factors. Using the methodology of Cochrane Collaboration, we did a systematic and meta-analysis of all know randomised controlled trials which compared adjuvant radiotherapy versus no radiotherapy following surgery for patients with stage I endometrial cancer. The meta-analysis was carried out on four trials (three published and one unpublished) and a total of 1770 patients. The addition of pelvic external beam radiotherapy to surgery reduced locoregional recurrence, a relative risk (RR) of 0.28 [95% confidence interval (CI) 0.17-0.44, P < 0.00001], which is a 72% reduction in the risk of pelvic relapse (95% CI 56% to 83%) and an absolute risk reduction of 6% (95% CI of 4% to 8%). The reduction in the risk of locoregional recurrence did not translate into a reduction in the risks of death from all causes, endometrial cancer death or distant recurrence. A subgroup analysis showed a trend towards the reduction in the risks of death from all causes and endometrial cancer in patients with multiple high risk factors (including stage 1c and grade 3). External beam pelvic radiotherapy should be considered in patients with multiple high-risk features including stage 1c and grade 3. However, it carries an inherent risk of damage and toxicity and should be avoided in stage 1 endometrial cancer patients with no high risk factors.
spellingShingle Kong, A
Simera, I
Collingwood, M
Williams, C
Kitchener, H
Adjuvant radiotherapy for stage I endometrial cancer: systematic review and meta-analysis.
title Adjuvant radiotherapy for stage I endometrial cancer: systematic review and meta-analysis.
title_full Adjuvant radiotherapy for stage I endometrial cancer: systematic review and meta-analysis.
title_fullStr Adjuvant radiotherapy for stage I endometrial cancer: systematic review and meta-analysis.
title_full_unstemmed Adjuvant radiotherapy for stage I endometrial cancer: systematic review and meta-analysis.
title_short Adjuvant radiotherapy for stage I endometrial cancer: systematic review and meta-analysis.
title_sort adjuvant radiotherapy for stage i endometrial cancer systematic review and meta analysis
work_keys_str_mv AT konga adjuvantradiotherapyforstageiendometrialcancersystematicreviewandmetaanalysis
AT simerai adjuvantradiotherapyforstageiendometrialcancersystematicreviewandmetaanalysis
AT collingwoodm adjuvantradiotherapyforstageiendometrialcancersystematicreviewandmetaanalysis
AT williamsc adjuvantradiotherapyforstageiendometrialcancersystematicreviewandmetaanalysis
AT kitchenerh adjuvantradiotherapyforstageiendometrialcancersystematicreviewandmetaanalysis